# Dogwood Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Dogwood Therapeutics, Inc.). ## Overview Dogwood Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing novel antiviral and pain-related therapies. Following its October 2024 combination, the company made Halneuron its lead program while continuing to evaluate IMC-1 and IMC-2 for herpesvirus-related disease burden, fibromyalgia, and Long-COVID-related fatigue. ## Products & services • Halneuron® clinical development program for pain indications • IMC-1 fixed-dose antiviral/anti-inflammatory combination • IMC-2 fixed-dose antiviral/anti-inflammatory combination • Clinical trial and drug development activities • Business development for licensing and partnership deals - **Lead clinical program** (40%) — Halneuron® and related development work targeting pain and neuropathic conditions. - **Antiviral combination candidates** (35%) — IMC-1 and IMC-2 fixed-dose combinations intended to suppress herpesvirus activation and replication. - **Clinical development services** (20%) — Internal R&D, trial execution, and manufacturing support for pipeline advancement. - **Business development and partnering** (5%) — Out-licensing, collaboration, and partnership efforts to fund and advance programs. - Halneuron® clinical development program for pain indications - IMC-1 fixed-dose antiviral/anti-inflammatory combination - IMC-2 fixed-dose antiviral/anti-inflammatory combination - Clinical trial and drug development activities - Business development for licensing and partnership deals ## Customers Dogwood does not currently sell commercial products; its primary counterparties are clinical investigators, contract research and manufacturing partners, and potential licensing or development partners. The company’s future end customers would be patients with pain, fibromyalgia, Long-COVID fatigue, or herpesvirus-related disease, but near-term value creation depends on regulators and partners rather than product sales. - **Clinical development partners** (primary) — CROs, trial sites, and manufacturers that execute studies and supply drug product for Halneuron, IMC-1, and IMC-2. - **Pharmaceutical licensing partners** (primary) — Potential partners that could fund or co-develop IMC-1 and IMC-2 in exchange for rights or economics. - **Patients with unmet-needs indications** (secondary) — Patients with fibromyalgia, neuropathic pain, or Long-COVID fatigue who represent the eventual therapeutic market. - **Regulatory stakeholders** (primary) — FDA and other stakeholders that determine approvable endpoints and development pathways. - Clinical trial sites and investigators running the company’s studies - CROs and manufacturing vendors supporting development work - Potential pharma partners for IMC-1 and IMC-2 licensing - Future patients with pain, fibromyalgia, or Long-COVID fatigue - Regulators and key opinion leaders influencing trial endpoints ## Geography The company is headquartered in the United States and appears to conduct its core operations there. The disclosed business is development-stage and does not yet generate product revenue, so geography is mainly relevant through U.S.-based financing, clinical operations, and regulatory oversight rather than sales mix. - United States is the operating base and headquarters market - Clinical and regulatory activities are centered on U.S. development pathways - No product revenue geography is disclosed because the company has none - Financing activity is primarily U.S.-market based - Exposure is driven more by U.S. capital markets than sales concentration ## Strategy Dogwood’s strategy is to advance Halneuron as the lead program while preserving optionality on IMC-1 and IMC-2 through partnering and regulatory alignment. Near term, the company’s most important task is securing financing to continue clinical trials and avoid delaying development plans. - **Secure additional financing** (short-term) — Cash is expected to fund operations only through the first quarter of 2026. - **Advance Halneuron clinical development** (short-term) — Halneuron is the lead program and the main focus of day-to-day operations. - **Partner IMC-1 and IMC-2** (medium-term) — Partnerships can offset development costs and improve the odds of progressing programs. - Advance Halneuron as the primary day-to-day focus - Seek a Phase 3 partner for IMC-1 to reduce funding burden - Preserve IMC-2 optionality for Long-COVID fatigue and EBV-related disease - Use FDA endpoint alignment to improve development feasibility - Raise capital through equity, debt, or collaborations ## Risks Dogwood is a pre-revenue biotech with substantial going-concern risk, so its ability to fund trials is central to survival and value creation. Program risk is also high because clinical outcomes, FDA endpoint acceptance, and partner interest will determine whether Halneuron, IMC-1, or IMC-2 can advance. As with most development-stage pharmaceutical companies, dilution, trial delays, and regulatory uncertainty are major risks. - **Insufficient liquidity and going-concern risk** [critical] — Cash on hand is expected to fund operations only through the first quarter of 2026. - **Clinical development failure or delay** [high] — The company depends on successful trial execution to create value and attract partners. - **Regulatory and endpoint uncertainty** [high] — Approval pathways depend on FDA agreement on endpoints and trial design. - **Partnering and funding execution risk** [high] — The company needs collaboration or licensing deals to advance some programs efficiently. - **Dilution from future capital raises** [medium] — Additional funding may come from equity or equity-linked securities. - Going-concern risk if new financing is not secured in time - Clinical trial failure or delay could halt pipeline progress - FDA endpoint or approval risk for IMC-2 and other programs - Partnering risk for IMC-1 Phase 3 and other collaborations - Dilution risk from equity or equity-linked financing ## Accounting Dogwood’s accounting is dominated by development-stage expense recognition rather than revenue accounting, since it has not generated product sales. Investors should watch estimates tied to clinical trial costs, legal and professional fees from the combination, and any financing-related costs that can move reported cash burn and equity dilution. - **Research and development expense recognition** — Affects reported burn rate and comparability across periods - **Financing transaction costs** — Affects cash flow presentation and equity balances - **Going-concern assessment** — Material disclosure affecting investor perception of solvency - **Combination-related legal and professional fees** — Impacts operating expense trend - No product revenue yet, so results are driven by expense recognition - R&D expense reflects clinical trials, manufacturing, and personnel costs - G&A includes legal, professional, franchise tax, and public-company costs - Financing proceeds and offering costs affect cash and equity accounting - Going-concern disclosure reflects management judgment on liquidity --- *Last updated: 2026-04-28T20:02:04.977720+00:00*